Trial · NCT07911293
Intratumoral Chlorine Dioxide Injection in Advanced Solid Tumors
NCT07911293, Phase 1, Not yet recruiting, SunGlow Innovations LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intratumoral Chlorine Dioxide Injection in Advanced Solid Tumors. Trials, record NCT07911293. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911293
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intratumoral Chlorine Dioxide Injection in Advanced Solid Tumors
- NCT number
- NCT07911293
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 50 participants, estimated
- Lead sponsor
- SunGlow Innovations LLC
- Conditions
- Solid Tumor, Neoplasms
- Interventions
- Chlorine Dioxide Injection 2%
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with dose-limiting toxicities | 28 days after each treatment session | Dose-limiting toxicities as defined in the protocol (Section 8), assessed after each treatment session. |
| Primary | Number of participants with treatment-emergent adverse events | From first treatment session up to 12 months | Any adverse event graded by CTCAE v5.0, from the first treatment session onward. |
| Primary | Number of participants with grade 3 or higher adverse events | From first treatment session up to 12 months | Adverse events of CTCAE v5.0 grade 3 or higher. |
| Primary | Number of participants with serious adverse events | From first treatment session up to 12 months | Serious adverse events as defined in 21 CFR 312.32. |
| Primary | Number of participants with adverse events related to study drug | From first treatment session up to 12 months | Adverse events assessed by the investigator as possibly, probably or definitely related to Chlorine Dioxide Injection 2%. |
| Primary | Percentage of deliveries with solution outside the lesion boundary | During each treatment session | Number of deliveries in which intraprocedural imaging shows delivered solution outside the target lesion boundary, divided by the total number of deliveries, expressed as a percentage. |
| Primary | Percentage of deliveries terminated by a mandatory stopping rule | During each treatment session | Number of deliveries terminated by a stopping rule defined in the protocol (Section 7.6), divided by the total number of deliveries, expressed as a percentage. |
| Primary | Number of participants with non-target tissue injury | During each treatment session and up to 28 days after | Injury to tissue outside the treatment zone attributable to delivered solution, assessed clinically and on imaging. |
| Secondary | Lesion-level complete non-viable radiological response rate | 7 to 28 days after the last treatment session | Percentage of target lesions with no residual viable tumor on contrast-enhanced imaging. |
| Secondary | Patient-level complete non-viable radiological response rate | 7 to 28 days after the last treatment session | Percentage of participants with complete non-viable response of all lesions, among participants in whom all visible lesions were injected. |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07911293
GET https://conductscience.org/api/trials/v1/NCT07911293/registered?page=2